ClinicalTrials.gg
CompletedNCT04449939Updated Sep 30, 2021

A Study of Subcutaneous KY1005 in Healthy Volunteers

A Phase 1 interventional study of KY1005 in Immune System Diseases, sponsored by Kymab Limited. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-30.

Sponsored by Kymab Limited (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration, with i.v. KY1005 as a reference treatment.

02

Conditions studied

  • Immune System Diseases
03

In context

Immune System Diseases

428 studies on the registry are indexed under Immune System Diseases; 86 are open to participants now.

This study's enrollment of 24 is below the median of 66 across 317 interventional studies indexed under Immune System Diseases.

Browse Immune System Diseases studies →

Lead sponsor

Kymab Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

First submitted before Kymab Limited became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 18-45 years at screening
  • Body weight 60-120 kg
  • (BMI) in the range 18.0-30.0 kg/m\^2 (inclusive)
  • Deemed healthy on the basis of a clinical history, physical examination, , vital signs and laboratory tests of blood and urine

Exclusion criteria

Exclusion Criteria:

  • abnormal findings at the screening assessment; acute or chronic illness; clinically relevant abnormal medical history or concurrent medical condition; positive tests for , , (HIV)
  • Drug or alcohol abuse
  • Use of over-the-counter medication (with the exception of paracetamol [acetaminophen]) during the 7 days before the first dose of trial medication, or prescribed medication during the 28 days before first dose of trial medication
  • Participation in other clinical trials of unlicensed medicines within the 3 months or 5 half-lives, whichever is longer, before admission to this study
  • Loss of more than 400 mL blood, within the previous 3 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1

    Single dose of KY1005 by i.v. infusion

    Drug: KY1005

  • Experimental
    Group 2

    Single lower dose KY1005 by s.c. injection

    Drug: KY1005

  • Experimental
    Group 3

    Single higher dose KY1005 by s.c. injections

    Drug: KY1005

Interventions

  • DrugKY1005

    A human anti-OX40 ligand monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) after infusion

    Time frame: Baseline to day 92

  2. Time at which Cmax is observed after infusion (tmax)

    Time frame: Baseline to day 92

  3. Area under the concentration time curve from time 0 to last observation (AUC 0-t)

    Time frame: Baseline to day 92

  4. Area under the concentration time curve from time 0 to infinity (AUC0-inf)

    Time frame: Baseline to day 92

  5. Systemic clearance after i.v. infusion (CL)

    Time frame: Baseline to day 92

  6. Apparent systemic clearance after s.c. injection (CL/F)

    Time frame: Baseline to day 92

  7. Volume of distribution during the terminal phase after i.v. infusion (Vz)

    Time frame: Baseline to day 92

  8. Apparent volume of distribution after s.c. injection (Vz/F)

    Time frame: Baseline to day 92

  9. Steady-state volume of distribution after i.v. infusion (Vss)

    Time frame: Baseline to day 92

  10. Weight-normalised Vss and Vz

    Time frame: Baseline to day 92

  11. Half-life t½

    Time frame: Baseline to day 92

  12. Dose-normalised Cmax (Cmax/D) following s.c. and i.v. administration

    Time frame: Baseline to day 92

  13. Absolute bioavailability (F) calculated as the ratio of AUC0-inf/D after i.v. and s.c. infusion

    Time frame: Baseline to day 92

  14. Dose-normalised AUC0-inf (AUC0-inf/D) following s.c. and i.v. administration

    Time frame: Baseline to day 92

Secondary outcomes

  1. Occurrence of TEAE

    Time frame: Baseline to day 92

  2. Occurrence of TESAE

    Time frame: Baseline to day 92

  3. Occurrence of local injection site reactions

    Time frame: Baseline to day 92

  4. Changes in blood pressure mmHg (as a measure of safety and tolerability)

    Time frame: Baseline to day 92

  5. Changes in respiratory rate measured as breaths per minute (as a measure of safety and tolerability)

    Time frame: Baseline to day 92

  6. Changes in heart rate bpm (as a measure of safety and tolerability)

    Time frame: Baseline to day 92

  7. Changes in tympanic temperature °C (as a measure of safety and tolerability)

    Time frame: Baseline to day 92

  8. Changes in electrocardiograms PR, QR, QRS and QT intervals (as a measure of safety and tolerability)

    Time frame: Baseline to day 92

Other outcomes

  1. Serum anti-KY1005 antibody titres

    Time frame: Baseline to day 92

  2. Incidence of anti-KY1005 antibodies

    Time frame: Baseline to day 92

07

Study locations

1 site
  • Hammersmith Medicines Research
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2020, 4 months.

Of 25 industry-sponsored phase 1 interventional studies under Immune System Diseases, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's 4 months is below that.

Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 5 and three quarters within 69.

Immune System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 29, 2020
StartActual
Jul 7, 2020
Primary completionActual
Nov 30, 2020
CompletionActual
Nov 30, 2020
Last update
Sep 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04449939
Lead sponsor
Kymab Limited
Responsible party
Sponsor
First posted
Jun 29, 2020
Start date
Jul 7, 2020
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Last update
Sep 30, 2021

Study contacts

Adeep Puri, MBBS JCPTGP MPhil
principal investigator · Hammersmith Medicines Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion